CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.

FEBS Open Bio · 2023 · PMC10315799 · PMID 37157185

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

marginal significanceP = 0.058so close (0.05 < p ≤ 0.1)

In addition, the hazard of death for mice treated with the combination is 45.5% of the hazard for mice treated with CCR4‐IL2 IT with a marginal significance ( P = 0.058).

also in 3,086 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.